Caribou Biosciences

Performance

About Caribou Biosciences

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases. Led by its proprietary chRDNA genome-editing technology, the company pioneers off-the-shelf CAR-T cell therapies with enhanced specificity and activity to treat hematologic malignancies. Headquartered in Berkeley, California, Caribou advances therapies through genome editing strategies such as multiplex gene knockout, insertion, and immune cloaking to broaden patient access and accelerate treatment timelines.